ArticleOncology letters2017
Clinical characteristics and treatment outcomes of parathyroid carcinoma: A retrospective review of 234 cases.
Article in Oncology letters, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 3 syntheses or guidelines pooled it, 54 citations in OpenAlex.
- [Frozen section in oncologic endocrine surgery].Chirurgie (Heidelberg, Germany) · 2025Pooled it
- Guideline
- Giant parathyroid tumours in primary hyperparathyroidism: a systematic review.Langenbeck's archives of surgery · 2022Pooled it
- Parathyroid Carcinoma Revisited: Clinical and Pathological Insights From Two Decades of Experience.Clinical endocrinology · 2026Article
- Intrathyroidal parathyroid carcinoma in a patient with multiple endocrine neoplasia type 1.JCEM case reports · 2026Article
- Revisiting parathyroid carcinoma through the lens of the 2022 WHO classification.Hormones (Athens, Greece) · 2026Article
- Critical Insights into Parathyroid Cancer.Journal of cancer science and clinical therapeutics · 2026Article
- Case Report: The clear cell variant of papillary thyroid carcinoma: a clinicopathologic study of four cases with emphasis onFrontiers in oncology · 2026Article
- Parathyroid carcinoma: epidemiology and genetics.Endocrine oncology (Bristol, England) · 2026Review
- Diagnostic and Therapeutic Challenges in Parathyroid Cancers: 15 Years' Experience in a Tertiary Center and an Endocrine Surgery Referral Hospital.Journal of clinical medicine · 2025Article
- Article
- Biochemical and Structural Response to Lenvatinib in Metastatic Parathyroid Carcinoma: Case Report.Clinical medicine insights. Endocrinology and diabetes · 2025Article
- Risk Factors of Distant Metastatic Parathyroid Carcinoma and Insights into Therapeutic Perspectives.Annals of surgical oncology · 2024Observational
- Detection and identification of circulating tumor cells in parathyroid tumors and correlation analysis with clinicopathological features.Endocrine · 2024Article
- The significance of an immunohistochemical marker-based panel in assisting the diagnosis of parathyroid carcinoma.Endocrine · 2024Article
- Parathyroid carcinoma in a patient with primary hyperparathyroidism mimicking parathyroid adenoma.BMJ case reports · 2023Article
- Time to Recurrence as a Prognostic Factor in Parathyroid Carcinoma.Journal of the Endocrine Society · 2023Article
- Parathyroid carcinoma: lessons from a rare malignancy of head and neck-a case series.Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India · 2023Article
- Evaluation of factors predicting postoperative recurrence and metastasis of parathyroid cancer: a single-center study.World journal of surgical oncology · 2023Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Parathyroid carcinoma (PC) is one of the rarest known types of cancer and has a moderate prognosis, with estimated 5- and 10-year overall survival rates between 78-85% and between 49-70%, respectively. To raise awareness of this disease, and to optimize its diagnosis, clinical management and prognosis, the present study retrospectively reviewed 234 cases of PC. A total of 226 cases of PC, which were archived between 1984 and 2015 in the three major databases of the Chinese population, were retrieved and pooled with the 8 cases diagnosed and treated at the Department of Thyroid Surgery of The First Hospital of Jilin University (Changchun, China) between June 2008 and December 2015. The clinicopathological features, diagnosis, surgical procedures and outcomes of these cases of PC were investigated. The review revealed that misdiagnosis has been a considerable issue, with >80% of the patients misdiagnosed prior to surgery, and the accuracy of intraoperative diagnosis based on frozen sections was only 15.04%. The use of radical resection as first-line therapy significantly improved the disease-free survival by ~8 years (log-rank, 20.956; P<0.001); and, at relapse, reoperation prolonged patient survival by ~7 years (log-rank, 35.322; P<0.001). Consistently, a Cox proportional hazards analysis indicated that radical resection as a first-line therapy reduced the risk of postoperative recurrence (P=0.030), and that reoperation following recurrence significantly improved patient survival (P=0.030). The 5- and 10-year cumulative disease-specific survival rates of the cases of PC were 83 and 67%, respectively. Notably, an increased mortality rate was observed among males with PC compared with female patients with PC. In summary, in the past 32 years (1984-2015), the majority of patients with PC have been misdiagnosed. Performing radical resection as the first-line therapy significantly reduces recurrence and improves patient survival time; and, following relapse, subsequent surgery has also been demonstrated to be an effective approach.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.